+91 8766 590 1366 sales@chemreports.com

Your Order

Home Reports

Bortezomib API Global Market

Bortezomib API Global Market

Global Bortezomib API Market Research Report 2025

This report on the global bortezomib api market research report 2025 offers a comprehensive analysis of market size, growth drivers, emerging trends, regional perfor

Pages: 210

Format: PDF

Date: 12-2025

Select Licence

Description Table of Content Key Players & Segment Request for Free Sample

Global Bortezomib API Market Overview

The Global Bortezomib API Market is a specialized segment of the oncology active pharmaceutical ingredients (API) industry, focused on the supply of Bortezomib used primarily in the treatment of multiple myeloma and mantle cell lymphoma. As a proteasome inhibitor with established clinical efficacy, Bortezomib continues to play a critical role in hematological cancer therapy, sustaining long-term demand for high-quality APIs.

Chem Reports estimates that the Bortezomib API Market was valued at USD xxxx units in 2024 and is expected to reach USD xxxx units by 2035, expanding at a CAGR of xx% during the forecast period (2025–2035). Market growth is driven by increasing cancer incidence, wider adoption of generic injectable oncology drugs, and the expansion of API manufacturing capabilities in cost-competitive regions.

The market assessment incorporates historical and current data, analyzing regulatory environments, manufacturing complexity, competitive dynamics, technological advancements in synthesis and purification, and evolving demand across regulated and semi-regulated markets.

Impact of COVID-19 on the Bortezomib API Market

The COVID-19 pandemic caused short-term disruptions in the Bortezomib API market due to manufacturing slowdowns, supply-chain interruptions, and logistical constraints. Delays in raw material procurement and temporary shutdowns affected API output during the early stages of the pandemic.

However, oncology treatments remained a healthcare priority, limiting long-term demand erosion. Post-pandemic recovery was supported by normalization of global supply chains, increased inventory planning by pharmaceutical companies, and renewed focus on uninterrupted supply of critical cancer drugs.

Market Segmentation Analysis

By Type (Purity Level)

Purity ≥ 98%

  • Used primarily in semi-regulated and cost-sensitive markets
  • Suitable for manufacturers targeting generic injectable formulations
  • Cost-efficient option with stable demand

Purity ≥ 99%

  • Preferred for regulated markets with stringent quality requirements
  • Higher demand from multinational formulation companies
  • Increasing adoption due to tighter regulatory scrutiny and quality standards

By Application

Injection

  • Dominant application segment
  • Bortezomib is predominantly administered via injectable formulations
  • Sustained demand from hospital and oncology treatment centers

Others

  • Includes limited research and specialty formulations
  • Small but strategically relevant segment for product development

Key Players Analysis

The Bortezomib API market is moderately consolidated, with competition centered on regulatory compliance, synthesis expertise, consistency of supply, and cost efficiency.

  • Scion Pharm Taiwan – Specialized API supplier with a strong presence in oncology molecules.
  • Vinkem Labs – Focuses on complex and high-potency APIs for global markets.
  • Shilpa Medicare Limited – Integrated player with strong oncology API and formulation capabilities.
  • Farmhispania Group – Known for high-quality APIs serving regulated markets.
  • ICROM – Specializes in high-potency APIs and complex synthesis.
  • TAPI Teva – Global leader in regulated-market APIs with strong compliance credentials.
  • Chem‑Stone (Guangzhou) – Cost-competitive producer supplying Asian markets.
  • Gland Chemicals – Expanding API portfolio with focus on injectables.
  • Dr. Reddy's Laboratories – Strong global footprint and vertically integrated oncology portfolio.
  • Qilu Pharmaceutical – Large-scale producer with growing international presence.
  • Chengdu Aslee Biopharmaceuticals – Focused on oncology APIs and intermediates.
  • Coresyn – Specialized manufacturer of niche and complex APIs.
  • Hubei Honch Pharmaceutical – Regional supplier emphasizing cost-efficient production.

Regional Analysis

North America

  • Strong demand driven by high prevalence of hematological cancers
  • Preference for ≥99% purity APIs
  • Strict regulatory requirements support premium pricing

Europe

  • Stable demand from generic injectable manufacturers
  • Emphasis on quality, traceability, and regulatory compliance
  • Presence of established oncology drug producers

Asia-Pacific

  • Fastest-growing regional market
  • India and China dominate API production and export
  • Rising domestic oncology drug consumption and manufacturing scale-up

South America

  • Gradual growth supported by expanding access to oncology treatments
  • High dependence on imported APIs

Middle East & Africa

  • Emerging market with long-term potential
  • Increasing cancer diagnosis rates and healthcare investment
  • Limited local API manufacturing capabilities

DRTO Analysis (Drivers, Restraints, Trends & Opportunities)

Drivers

  • Rising global incidence of multiple myeloma and mantle cell lymphoma
  • Sustained clinical relevance of Bortezomib as a first-line and combination therapy
  • Expanding penetration of generic injectable oncology drugs
  • Increasing outsourcing of complex API manufacturing to cost-efficient regions
  • Strong demand from regulated markets for high-purity oncology APIs

Restraints

  • High manufacturing complexity due to peptide-boronic acid chemistry
  • Stringent regulatory requirements for injectable oncology APIs
  • Capital-intensive production facilities and containment requirements
  • Pricing pressure from multiple generic API suppliers
  • Dependence on hospital-based injectable treatment protocols

Trends

  • Shift toward ≥99% purity APIs to meet stricter regulatory standards
  • Increasing vertical integration by API producers into injectable formulations
  • Growing focus on supply security and multi-source API procurement
  • Capacity expansion in India and China for high-potency oncology APIs
  • Emphasis on process optimization to improve yield and reduce costs

Opportunities

  • Growing oncology drug demand in emerging markets
  • Long-term supply agreements with global injectable manufacturers
  • Expansion into regulated markets through DMF and GMP approvals
  • Development of backward-integrated intermediates to reduce cost volatility
  • Rising demand from contract development and manufacturing organizations (CDMOs)

SWOT Analysis for Key Players

Strengths

  • Strong technical expertise in complex oncology API synthesis
  • Established regulatory approvals across multiple regions
  • Scalable manufacturing infrastructure
  • Long-standing relationships with injectable formulation companies

Weaknesses

  • High dependence on a limited number of oncology molecules
  • Margin compression due to generic competition
  • High compliance and quality-assurance costs
  • Long lead times for regulatory approvals and validations

Opportunities

  • Entry into premium regulated markets with high-purity APIs
  • Strategic alliances with global pharmaceutical companies
  • Portfolio expansion into adjacent oncology APIs
  • Increased outsourcing by innovator and generic drug manufacturers

Threats

  • Emergence of alternative therapies reducing long-term reliance on Bortezomib
  • Regulatory scrutiny leading to production or export delays
  • Supply-chain disruptions affecting raw materials
  • Intensifying competition from low-cost manufacturers

Porter’s Five Forces Analysis

Threat of New Entrants – Moderate

High technical expertise, regulatory barriers, and capital investment requirements limit new entrants, though emerging-market players continue to add capacity.

Bargaining Power of Suppliers – Moderate

Specialized intermediates provide suppliers some leverage; however, large API manufacturers mitigate this through backward integration and multi-vendor sourcing.

Bargaining Power of Buyers – High

Injectable formulation companies exert strong negotiating power due to multiple qualified API sources and price sensitivity.

Threat of Substitutes – Low to Moderate

While newer oncology therapies are emerging, Bortezomib remains a clinically established molecule, limiting immediate substitution risk.

Competitive Rivalry – High

Market competition is intense, driven by pricing, regulatory compliance, supply reliability, and consistency of quality.

Investor-Focused Executive Summary

The Global Bortezomib API Market represents a stable and demand-driven oncology API opportunity supported by the continued clinical relevance of Bortezomib in hematological cancer treatment. Despite the maturity of the molecule, sustained prescription volumes and the widespread use of generic injectables ensure long-term baseline demand.

From an investment perspective, the market offers predictable cash flows and moderate growth potential, particularly for manufacturers with strong regulatory credentials and cost-efficient production models. While pricing pressure is an inherent challenge, companies that achieve scale, backward integration, and diversified customer exposure are better positioned to protect margins.

Asia-Pacific will remain the global manufacturing hub, while North America and Europe will continue to drive value realization through regulated-market demand. Overall, the Bortezomib API market presents moderate risk with consistent returns, making it suitable for investors focused on oncology APIs, injectable drug supply chains, and regulated pharmaceutical manufacturing.

 

1. Market Overview of Bortezomib API Market
    1.1 Bortezomib API Market Market Overview
        1.1.1 Bortezomib API Market Product Scope
        1.1.2 Market Status and Outlook
    1.2 Bortezomib API Market Market Size by Regions:
    1.3 Bortezomib API Market Historic Market Size by Regions
    1.4 Bortezomib API Market Forecasted Market Size by Regions
    1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
        1.5.1 North America
        1.5.2 East Asia
        1.5.3 Europe
        1.5.4 South Asia
        1.5.5 Southeast Asia
        1.5.6 Middle East
        1.5.7 Africa
        1.5.8 Oceania
        1.5.9 South America
        1.5.10 Rest of the World
    1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
        1.6.1 Covid-19 Impact: Global GDP Growth,  Projections
        1.6.2 Covid-19 Impact: Commodity Prices Indices
        1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Bortezomib API Market Sales Market by Type
    2.1 Global Bortezomib API Market Historic Market Size by Type
    2.2 Global Bortezomib API Market Forecasted Market Size by Type
    2.3 Purity ? 98 %
    2.4 Purity ? 99 %
3. Covid-19 Impact Bortezomib API Market Sales Market by Application
    3.1 Global Bortezomib API Market Historic Market Size by Application
    3.2 Global Bortezomib API Market Forecasted Market Size by Application
    3.3 Injection
    3.4 Others
4. Covid-19 Impact Market Competition by Manufacturers
    4.1 Global Bortezomib API Market Production Capacity Market Share by Manufacturers
    4.2 Global Bortezomib API Market Revenue Market Share by Manufacturers
    4.3 Global Bortezomib API Market Average Price by Manufacturers
5. Company Profiles and Key Figures in Bortezomib API Market Business
    5.1 Scion Pharm Taiwan
        5.1.1 Scion Pharm Taiwan Company Profile
        5.1.2 Scion Pharm Taiwan Bortezomib API Market Product Specification
        5.1.3 Scion Pharm Taiwan Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.2 Vinkem Labs
        5.2.1 Vinkem Labs Company Profile
        5.2.2 Vinkem Labs Bortezomib API Market Product Specification
        5.2.3 Vinkem Labs Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.3 Shilpa Medicare Limited
        5.3.1 Shilpa Medicare Limited Company Profile
        5.3.2 Shilpa Medicare Limited Bortezomib API Market Product Specification
        5.3.3 Shilpa Medicare Limited Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.4 Farmhispania Group
        5.4.1 Farmhispania Group Company Profile
        5.4.2 Farmhispania Group Bortezomib API Market Product Specification
        5.4.3 Farmhispania Group Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.5 Icrom
        5.5.1 Icrom Company Profile
        5.5.2 Icrom Bortezomib API Market Product Specification
        5.5.3 Icrom Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.6 Tapi Teva
        5.6.1 Tapi Teva Company Profile
        5.6.2 Tapi Teva Bortezomib API Market Product Specification
        5.6.3 Tapi Teva Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.7 Chem-Stone(Guangzhou)
        5.7.1 Chem-Stone(Guangzhou) Company Profile
        5.7.2 Chem-Stone(Guangzhou) Bortezomib API Market Product Specification
        5.7.3 Chem-Stone(Guangzhou) Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.8 Gland Chemicals
        5.8.1 Gland Chemicals Company Profile
        5.8.2 Gland Chemicals Bortezomib API Market Product Specification
        5.8.3 Gland Chemicals Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.9 Dr. Reddy's Laboratories
        5.9.1 Dr. Reddy's Laboratories Company Profile
        5.9.2 Dr. Reddy's Laboratories Bortezomib API Market Product Specification
        5.9.3 Dr. Reddy's Laboratories Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.10 Qilu Pharmaceutial
        5.10.1 Qilu Pharmaceutial Company Profile
        5.10.2 Qilu Pharmaceutial Bortezomib API Market Product Specification
        5.10.3 Qilu Pharmaceutial Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.11 Chengdu Aslee Biopharmaceuticals
        5.11.1 Chengdu Aslee Biopharmaceuticals Company Profile
        5.11.2 Chengdu Aslee Biopharmaceuticals Bortezomib API Market Product Specification
        5.11.3 Chengdu Aslee Biopharmaceuticals Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.12 Coresyn
        5.12.1 Coresyn Company Profile
        5.12.2 Coresyn Bortezomib API Market Product Specification
        5.12.3 Coresyn Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
    5.13 Hubei Honch Pharmaceutical
        5.13.1 Hubei Honch Pharmaceutical Company Profile
        5.13.2 Hubei Honch Pharmaceutical Bortezomib API Market Product Specification
        5.13.3 Hubei Honch Pharmaceutical Bortezomib API Market Production Capacity, Revenue, Price and Gross Margin
6. North America
    6.1 North America Bortezomib API Market Market Size
    6.2 North America Bortezomib API Market Key Players in North America
    6.3 North America Bortezomib API Market Market Size by Type
    6.4 North America Bortezomib API Market Market Size by Application
7. East Asia
    7.1 East Asia Bortezomib API Market Market Size
    7.2 East Asia Bortezomib API Market Key Players in North America
    7.3 East Asia Bortezomib API Market Market Size by Type
    7.4 East Asia Bortezomib API Market Market Size by Application
8. Europe
    8.1 Europe Bortezomib API Market Market Size
    8.2 Europe Bortezomib API Market Key Players in North America
    8.3 Europe Bortezomib API Market Market Size by Type
    8.4 Europe Bortezomib API Market Market Size by Application
9. South Asia
    9.1 South Asia Bortezomib API Market Market Size
    9.2 South Asia Bortezomib API Market Key Players in North America
    9.3 South Asia Bortezomib API Market Market Size by Type
    9.4 South Asia Bortezomib API Market Market Size by Application
10. Southeast Asia
    10.1 Southeast Asia Bortezomib API Market Market Size
    10.2 Southeast Asia Bortezomib API Market Key Players in North America
    10.3 Southeast Asia Bortezomib API Market Market Size by Type
    10.4 Southeast Asia Bortezomib API Market Market Size by Application
11. Middle East
    11.1 Middle East Bortezomib API Market Market Size
    11.2 Middle East Bortezomib API Market Key Players in North America
    11.3 Middle East Bortezomib API Market Market Size by Type
    11.4 Middle East Bortezomib API Market Market Size by Application
12. Africa
    12.1 Africa Bortezomib API Market Market Size
    12.2 Africa Bortezomib API Market Key Players in North America
    12.3 Africa Bortezomib API Market Market Size by Type
    12.4 Africa Bortezomib API Market Market Size by Application
13. Oceania
    13.1 Oceania Bortezomib API Market Market Size
    13.2 Oceania Bortezomib API Market Key Players in North America
    13.3 Oceania Bortezomib API Market Market Size by Type
    13.4 Oceania Bortezomib API Market Market Size by Application
14. South America
    14.1 South America Bortezomib API Market Market Size
    14.2 South America Bortezomib API Market Key Players in North America
    14.3 South America Bortezomib API Market Market Size by Type
    14.4 South America Bortezomib API Market Market Size by Application
15. Rest of the World
    15.1 Rest of the World Bortezomib API Market Market Size
    15.2 Rest of the World Bortezomib API Market Key Players in North America
    15.3 Rest of the World Bortezomib API Market Market Size by Type
    15.4 Rest of the World Bortezomib API Market Market Size by Application
16 Bortezomib API Market Market Dynamics
    16.1 Covid-19 Impact Market Top Trends
    16.2 Covid-19 Impact Market Drivers
    16.3 Covid-19 Impact Market Challenges
    16.4 Porter?s Five Forces Analysis
18 Regulatory Information
17 Analyst's Viewpoints/Conclusions
18 Appendix
    18.1 Research Methodology
        18.1.1 Methodology/Research Approach
        18.1.2 Data Source
    18.2 Disclaimer

Market Segmentation Analysis

By Type (Purity Level)

Purity ≥ 98%

  • Used primarily in semi-regulated and cost-sensitive markets
  • Suitable for manufacturers targeting generic injectable formulations
  • Cost-efficient option with stable demand

Purity ≥ 99%

  • Preferred for regulated markets with stringent quality requirements
  • Higher demand from multinational formulation companies
  • Increasing adoption due to tighter regulatory scrutiny and quality standards

By Application

Injection

  • Dominant application segment
  • Bortezomib is predominantly administered via injectable formulations
  • Sustained demand from hospital and oncology treatment centers

Others

  • Includes limited research and specialty formulations
  • Small but strategically relevant segment for product development

Key Players Analysis

The Bortezomib API market is moderately consolidated, with competition centered on regulatory compliance, synthesis expertise, consistency of supply, and cost efficiency.

  • Scion Pharm Taiwan – Specialized API supplier with a strong presence in oncology molecules.
  • Vinkem Labs – Focuses on complex and high-potency APIs for global markets.
  • Shilpa Medicare Limited – Integrated player with strong oncology API and formulation capabilities.
  • Farmhispania Group – Known for high-quality APIs serving regulated markets.
  • ICROM – Specializes in high-potency APIs and complex synthesis.
  • TAPI Teva – Global leader in regulated-market APIs with strong compliance credentials.
  • Chem‑Stone (Guangzhou) – Cost-competitive producer supplying Asian markets.
  • Gland Chemicals – Expanding API portfolio with focus on injectables.
  • Dr. Reddy's Laboratories – Strong global footprint and vertically integrated oncology portfolio.
  • Qilu Pharmaceutical – Large-scale producer with growing international presence.
  • Chengdu Aslee Biopharmaceuticals – Focused on oncology APIs and intermediates.
  • Coresyn – Specialized manufacturer of niche and complex APIs.
  • Hubei Honch Pharmaceutical – Regional supplier emphasizing cost-efficient production.

Upto 24 to 48 hrs (Working Hours)

Upto 72 hrs max (Working Hours) - Weekends and Public Holidays

Single User License - Allows access to only one person to the report.

Multi User License - Allows sharing with max 5 persons within organization.

Corporate License – Can be shared across entire organization.

Online Payments with PayPal

Wire Transfer / Bank Transfer

Why Choose Us

24/7 Expert Support

At ChemReports, we understand that business decisions can’t wait. Our research specialists are available anytime to answer your queries and guide you through our reports, ensuring quick and reliable assistance.

Comprehensive Market Coverage

ChemReports provides 360° market analysis across materials, technologies, and global chemical sectors—helping you make confident business decisions.

Actionable Intelligence

We turn complex data into strategic insights to support fact-based decisions, market entry strategies, and competitive analysis.

Data Privacy & Security

Your personal and business information is completely secure with us. We value your trust and ensure strict confidentiality.

Customized Research

Need tailored insights? Our analysts provide custom reports built on authentic data and aligned with your specific business goals.

FAQs

Yes, we are providing all research support to get resolve all queries and concerns regarding the report. For all our clients.
Yes, we are providing complete customization in every report to fulfill your business needs.
Yes, we are providing regional and countries level analysis in the report, please mention the countries you are looking.
Yes, we are providing a discount for individuals and startups.
We offer access to more than one million market research reports. If the specific topic you need is not listed on our website, simply email us your requirements at sales@chemreports.com. Our research team will review your request and provide a customized report or the most relevant available study. We?re always happy to assist you with tailored solutions.